Shareholder alert: weiss law investigates infrastructure and zymergen inc.

New york , july 25, 2022 /prnewswire/ -- weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of zymergen inc. ("zymergen" or the "company") (nasdaq: zy), connected with the proposed acquisition of the company by ginkgo bioworks holdings, inc. ("ginkgo") (nyse: dna). under the terms of the merger agreement, the company's shareholders will receive 0.9179 shares of ginkgo common stock for each zymergen share owned, representing implied per-share merger consideration of approximately $2.68 based upon ginkgo's july 22, 2022 closing price of $2.92.
DNA Ratings Summary
DNA Quant Ranking